Develops and manufactures single-use medical devices. Produces vascular and non-vascular access infusion devices. Now — the numbers.
This is an established company with proven profits.
No real growth.
If every debt were paid off today, $711.9M would still be left in the vault — a solid cushion for hard times.
The market pays 7.6× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 77% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $1.5B in the vault; even if every debt were paid off, $711.9M would remain.
It pays out $0.02 per share each year — regular cash for whoever holds the stock.
The stock sits at $0.40. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 4 years, sales fell about 0% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.